These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28244723)

  • 1. The Ecstasy and Agony of Assay Interference Compounds.
    Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S
    ACS Infect Dis; 2017 Apr; 3(4):259-262. PubMed ID: 28244723
    [No Abstract]   [Full Text] [Related]  

  • 2. The Ecstasy and Agony of Assay Interference Compounds.
    Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S
    ACS Chem Neurosci; 2017 Mar; 8(3):420-423. PubMed ID: 28244737
    [No Abstract]   [Full Text] [Related]  

  • 3. Tackling reproducibility in academic preclinical drug discovery.
    Frye SV; Arkin MR; Arrowsmith CH; Conn PJ; Glicksman MA; Hull-Ryde EA; Slusher BS
    Nat Rev Drug Discov; 2015 Nov; 14(11):733-4. PubMed ID: 26388229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ecstasy and Agony of Assay Interference Compounds.
    Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S
    Biochemistry; 2017 Mar; 56(10):1363-1366. PubMed ID: 28244742
    [No Abstract]   [Full Text] [Related]  

  • 5. The Ecstasy and Agony of Assay Interference Compounds.
    Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S
    J Med Chem; 2017 Mar; 60(6):2165-2168. PubMed ID: 28244745
    [No Abstract]   [Full Text] [Related]  

  • 6. The Ecstasy and Agony of Assay Interference Compounds.
    Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S
    J Chem Inf Model; 2017 Mar; 57(3):387-390. PubMed ID: 28244743
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on The Ecstasy and Agony of Assay Interference Compounds.
    Kenny PW
    J Chem Inf Model; 2017 Nov; 57(11):2640-2645. PubMed ID: 29048168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Method Development and Application of an Accelerated Solution Stability Screen for Drug Discovery.
    Gomez-Sanchez R; Besley S; Zeliku Z; Young RJ
    SLAS Discov; 2020 Dec; 25(10):1191-1196. PubMed ID: 32522054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.
    Nijsen MJMA; Wu F; Bansal L; Bradshaw-Pierce E; Chan JR; Liederer BM; Mettetal JT; Schroeder P; Schuck E; Tsai A; Xu C; Chimalakonda A; Le K; Penney M; Topp B; Yamada A; Spilker ME
    CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):135-146. PubMed ID: 29349875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing and sustaining India's capacity for preclinical drug discovery.
    Lewis DI; Patel BK; Kumar BD; Medhi B
    Indian J Pharmacol; 2018; 50(5):225-226. PubMed ID: 30636824
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
    Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
    J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
    Cai XY; Thomas J; Cullen C; Gouty D
    Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ecstasy and Agony of Assay Interference Compounds.
    Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S
    ACS Chem Biol; 2017 Mar; 12(3):575-578. PubMed ID: 28244728
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioanalysis in drug discovery.
    Hill H
    Bioanalysis; 2011 Oct; 3(19):2155-8. PubMed ID: 21985408
    [No Abstract]   [Full Text] [Related]  

  • 15. Identifying initiation and elongation inhibitors of dengue virus RNA polymerase in a high-throughput lead-finding campaign.
    Smith TM; Lim SP; Yue K; Busby SA; Arora R; Seh CC; Wright SK; Nutiu R; Niyomrattanakit P; Wan KF; Beer D; Shi PY; Benson TE
    J Biomol Screen; 2015 Jan; 20(1):153-63. PubMed ID: 25252731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minipigs as models in drug discovery.
    Singh VK; Thrall KD; Hauer-Jensen M
    Expert Opin Drug Discov; 2016 Dec; 11(12):1131-1134. PubMed ID: 27546211
    [No Abstract]   [Full Text] [Related]  

  • 17. [Study on ion channel transporters as a target for the drug discovery].
    Imaizumi Y; Kaneko S
    Nihon Yakurigaku Zasshi; 2011 Dec; 138(6):227. PubMed ID: 22303567
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioengineering. Lung-on-a-chip breathes new life into drug discovery.
    Service RF
    Science; 2012 Nov; 338(6108):731. PubMed ID: 23139305
    [No Abstract]   [Full Text] [Related]  

  • 19. Current strategies in lead discovery.
    Webb ML
    Curr Pharm Biotechnol; 2010 Nov; 11(7):720. PubMed ID: 21077839
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent advances in virtual screening for drug discovery.
    Leung CH; Ma DL
    Methods; 2015 Jan; 71():1-3. PubMed ID: 25542642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.